Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01689363 · ClinicalTrials.gov registry record · Phase 2

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

A Phase 2 study, sponsored by Amphastar Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
253
Enrollment target

NCT01689363 is a Phase 2 study that has completed, run by Amphastar Pharmaceuticals. The registered enrollment target is 253 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01689363, a Phase 2 study, has completed, sponsored by Amphastar Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
253 participants
Enrollment target

Study Summary

This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.

Interventions

  • DRUG Saline
  • DRUG Histamine
  • DRUG Hyaluronidase

Trial Details

FieldValue
Enrollment Target 253 participants
Start Date 2012-09
Est. Completion 2012-12
Phase Phase 2

Sponsor

Amphastar Pharmaceuticals

21 total trials

What the Registry Record Tells You About NCT01689363

The ClinicalTrials.gov registry entry for NCT01689363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amphastar Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.

NCT01689363 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01689363 about?

NCT01689363 is a clinical study titled "Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)". This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.

What is the current status of trial NCT01689363?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 253 participants. The study started on 2012-09. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01689363?

The interventions under investigation include: Saline (DRUG), Histamine (DRUG), Hyaluronidase (DRUG).

Who is sponsoring clinical trial NCT01689363?

This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.